骨髓增生-话题@MedSci

#骨髓增生#

95篇内容 | 905人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2199814, encodeId=ee0e2199814c9, content=<a href='/topic/show?id=d7716530469' target=_blank style='color:#2F92EE;'>#流式细胞术#</a> <a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a> <a href='/topic/show?id=219d113658b2' target=_blank style='color:#2F92EE;'>#肿瘤患者筛查#</a>, objectTitle=采用流式细胞术对疑似和确诊骨髓增生异常肿瘤患者筛查和监测（MDS-PB13评分）, objectType=article, longId=822793, objectId=f950822e93f1, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=f950822e93f1, replyNumber=0, likeNumber=2, createdTime=2024-04-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f950822e93f1, moduleTitle=采用流式细胞术对疑似和确诊骨髓增生异常肿瘤患者筛查和监测（MDS-PB13评分）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f950822e93f1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1821820, encodeId=3ca4182182059, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=Ann Hematol：急性移植物抗宿主病增加骨髓增生异常综合征患者移植相关血栓性微血管病预测模型的风险和准确性, objectType=article, longId=302301, objectId=32c8302301b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32c8302301b4, replyNumber=0, likeNumber=40, createdTime=2022-06-08, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32c8302301b4, moduleTitle=Ann Hematol：急性移植物抗宿主病增加骨髓增生异常综合征患者移植相关血栓性微血管病预测模型的风险和准确性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32c8302301b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821818, encodeId=8bae1821818a4, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=haematol： DDX41突变在意义不明的特发性血细胞减少症、骨髓增生异常综合征或急性髓细胞白血病患者中的独特种族特征 , objectType=article, longId=299300, objectId=6c4d299300d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c4d299300d6, replyNumber=0, likeNumber=51, createdTime=2022-04-21, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c4d299300d6, moduleTitle=haematol： DDX41突变在意义不明的特发性血细胞减少症、骨髓增生异常综合征或急性髓细胞白血病患者中的独特种族特征 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c4d299300d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821816, encodeId=7791182181657, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=小剂量阿克拉霉素治疗骨髓增生异常综合征2例, objectType=article, longId=220752, objectId=737a220e52dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=737a220e52dc, replyNumber=0, likeNumber=0, createdTime=2022-01-28, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=737a220e52dc, moduleTitle=小剂量阿克拉霉素治疗骨髓增生异常综合征2例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=737a220e52dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821819, encodeId=f8dc1821819b6, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=Leukemia ：罗特西普用于骨髓增生异常综合征/骨髓增生性肿瘤伴环状铁粒幼细胞和血小板增多症, objectType=article, longId=299893, objectId=d33a2998931b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d33a2998931b, replyNumber=0, likeNumber=62, createdTime=2022-10-22, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d33a2998931b, moduleTitle=Leukemia ：罗特西普用于骨髓增生异常综合征/骨髓增生性肿瘤伴环状铁粒幼细胞和血小板增多症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d33a2998931b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821817, encodeId=0f31182181e8c, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=AJH：脑静脉血栓形成和骨髓增生性肿瘤：74 例连续病例的三中心研究, objectType=article, longId=292083, objectId=782c292083cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782c292083cf, replyNumber=0, likeNumber=38, createdTime=2022-10-06, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782c292083cf, moduleTitle=AJH：脑静脉血栓形成和骨髓增生性肿瘤：74 例连续病例的三中心研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782c292083cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821814, encodeId=8e951821814ee, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响, objectType=article, longId=209205, objectId=36c4209205ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c4209205ac, replyNumber=0, likeNumber=41, createdTime=2021-11-02, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c4209205ac, moduleTitle=JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c4209205ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821810, encodeId=f872182181063, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, objectType=article, longId=204980, objectId=817f204980c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=817f204980c0, replyNumber=0, likeNumber=36, createdTime=2021-01-14, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=817f204980c0, moduleTitle=Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=817f204980c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821815, encodeId=5e1818218159e, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=Leukemia：艾曲波帕eltrombopag在骨髓增生异常综合征的PDX模型中的临床前评估, objectType=article, longId=213632, objectId=794621363207, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=794621363207, replyNumber=0, likeNumber=40, createdTime=2021-08-03, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=794621363207, moduleTitle=Leukemia：艾曲波帕eltrombopag在骨髓增生异常综合征的PDX模型中的临床前评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=794621363207)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821811, encodeId=8eae1821811e3, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, objectType=article, longId=205306, objectId=719320530679, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=719320530679, replyNumber=0, likeNumber=33, createdTime=2021-06-16, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=719320530679, moduleTitle=TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=719320530679)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821812, encodeId=9199182181294, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=J Clin Oncol：来那度胺可恢复骨髓增生异常综合征对EPOα的敏感性，改善患者预后, objectType=article, longId=206296, objectId=888e206296e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=888e206296e7, replyNumber=0, likeNumber=0, createdTime=2021-06-30, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=888e206296e7, moduleTitle=J Clin Oncol：来那度胺可恢复骨髓增生异常综合征对EPOα的敏感性，改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=888e206296e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821813, encodeId=56f8182181325, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=J Clin Oncol：骨髓增生异常综合征 | 基于临床和遗传特征的个体化预后预测, objectType=article, longId=206824, objectId=f620206824b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f620206824b5, replyNumber=0, likeNumber=39, createdTime=2021-04-12, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f620206824b5, moduleTitle=J Clin Oncol：骨髓增生异常综合征 | 基于临床和遗传特征的个体化预后预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f620206824b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821809, encodeId=5f0e1821809da, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, objectType=article, longId=203861, objectId=324020386153, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=324020386153, replyNumber=0, likeNumber=30, createdTime=2021-08-06, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=324020386153, moduleTitle=中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=324020386153)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821807, encodeId=6b49182180e7c, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=EClinical Medicine：骨髓增生性肿瘤患者炎症性黄斑变性风险增加, objectType=article, longId=200469, objectId=e57220046940, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e57220046940, replyNumber=0, likeNumber=27, createdTime=2021-01-17, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e57220046940, moduleTitle=EClinical Medicine：骨髓增生性肿瘤患者炎症性黄斑变性风险增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e57220046940)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821808, encodeId=d5ed1821808e8, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=Nature：骨髓增生性肿瘤是如何具有遗传性的？, objectType=article, longId=202243, objectId=4384202243ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4384202243ef, replyNumber=0, likeNumber=46, createdTime=2020-11-05, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4384202243ef, moduleTitle=Nature：骨髓增生性肿瘤是如何具有遗传性的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4384202243ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821806, encodeId=5c85182180681, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, objectType=article, longId=197791, objectId=327a19e79151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=327a19e79151, replyNumber=0, likeNumber=32, createdTime=2020-10-04, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=327a19e79151, moduleTitle=FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=327a19e79151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821805, encodeId=b207182180544, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=ARCH PATHOL LAB MED：来自儿童肿瘤组AAML0431的报告唐氏综合征、骨髓增生异常综合征和急性髓系白血病的病理特征, objectType=article, longId=194494, objectId=835e19449456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=835e19449456, replyNumber=0, likeNumber=32, createdTime=2020-11-23, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=835e19449456, moduleTitle=ARCH PATHOL LAB MED：来自儿童肿瘤组AAML0431的报告唐氏综合征、骨髓增生异常综合征和急性髓系白血病的病理特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=835e19449456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821800, encodeId=c01f1821800ed, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展, objectType=article, longId=184424, objectId=be5518442420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be5518442420, replyNumber=0, likeNumber=41, createdTime=2020-02-13, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be5518442420, moduleTitle=聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be5518442420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821801, encodeId=a53b182180183, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=NEJM： Luspatercept治疗骨髓增生异常综合征患者贫血, objectType=article, longId=186022, objectId=04e1186022ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04e1186022ee, replyNumber=0, likeNumber=32, createdTime=2020-05-11, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04e1186022ee, moduleTitle=NEJM： Luspatercept治疗骨髓增生异常综合征患者贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04e1186022ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1821797, encodeId=5a561821e971e, content=<a href='/topic/show?id=d1ba10196122' target=_blank style='color:#2F92EE;'>#骨髓增生#</a>, objectTitle=2019 西班牙指南：靶向深度测序在骨髓增生异常综合征和慢性粒单核细胞白血病中的应用, objectType=article, longId=183147, objectId=cbf918314e73, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf918314e73, replyNumber=0, likeNumber=29, createdTime=2020-03-28, rootId=0, userName=fengyqf, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf918314e73, moduleTitle=2019 西班牙指南：靶向深度测序在骨髓增生异常综合征和慢性粒单核细胞白血病中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf918314e73)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

骨髓增生

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#流式细胞术# #骨髓增生# #肿瘤患者筛查#

采用流式细胞术对疑似和确诊骨髓增生异常肿瘤患者筛查和监测（MDS-PB13评分）

2024-04-22发表于上海

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

Ann Hematol：急性移植物抗宿主病增加骨髓增生异常综合征患者移植相关血栓性微血管病预测模型的风险和准确性

2022-06-08

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

haematol： DDX41突变在意义不明的特发性血细胞减少症、骨髓增生异常综合征或急性髓细胞白血病患者中的独特种族特征

2022-04-21

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

小剂量阿克拉霉素治疗骨髓增生异常综合征2例

2022-01-28

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

Leukemia ：罗特西普用于骨髓增生异常综合征/骨髓增生性肿瘤伴环状铁粒幼细胞和血小板增多症

2022-10-22

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

AJH：脑静脉血栓形成和骨髓增生性肿瘤：74 例连续病例的三中心研究

2022-10-06

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

JCO：口服阿扎胞苷对低风险骨髓增生异常综合征患者的影响

2021-11-02

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

Aprea的Eprenetapopt尚未达到治疗TP53突变性骨髓增生异常综合症的主要终点

2021-01-14

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

Leukemia：艾曲波帕eltrombopag在骨髓增生异常综合征的PDX模型中的临床前评估

2021-08-03

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

TP53突变型骨髓增生异常综合症：Eprenetapopt未达到III期研究的主要终点

2021-06-16

仁心济世 (审核中...)

前往app查看评论内容

#骨髓增生#

J Clin Oncol：来那度胺可恢复骨髓增生异常综合征对EPOα的敏感性，改善患者预后

2021-06-30

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

J Clin Oncol：骨髓增生异常综合征 | 基于临床和遗传特征的个体化预后预测

2021-04-12

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

中国国家药品管理局批准ATG-016（Eltanexor）治疗高危骨髓增生异常综合征的I / II期临床试验

2021-08-06

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

EClinical Medicine：骨髓增生性肿瘤患者炎症性黄斑变性风险增加

2021-01-17

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

Nature：骨髓增生性肿瘤是如何具有遗传性的？

2020-11-05

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

FDA批准地西他滨/cedazuridine联合治疗骨髓增生异常综合征

2020-10-04

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

ARCH PATHOL LAB MED：来自儿童肿瘤组AAML0431的报告唐氏综合征、骨髓增生异常综合征和急性髓系白血病的病理特征

2020-11-23

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

聚焦阿扎胞苷联合治疗骨髓增生异常综合征的重磅进展

2020-02-13

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

NEJM： Luspatercept治疗骨髓增生异常综合征患者贫血

2020-05-11

fengyqf (审核中...)

前往app查看评论内容

#骨髓增生#

2019 西班牙指南：靶向深度测序在骨髓增生异常综合征和慢性粒单核细胞白血病中的应用

2020-03-28

科室
- - 订阅+
  - 更多科室
工具
服务